Novo Nordisk A/S Common Stock (NVO)
75.21
+0.58 (0.78%)
NYSE · Last Trade: Jun 9th, 1:53 PM EDT
The company is planning to soon begin combination studies, testing two of its drugs in weight loss.
Via Investor's Business Daily · June 9, 2025
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
Via Benzinga · June 9, 2025
Via The Motley Fool · June 8, 2025
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?
Via MarketBeat · June 7, 2025
Via The Motley Fool · June 7, 2025
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide.
Via Investor's Business Daily · June 6, 2025

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular degeneration, and kidney cancer.
Via Benzinga · June 6, 2025

Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of kidney cancer.
Via Benzinga · June 3, 2025

Via Benzinga · June 3, 2025

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.
Via Benzinga · June 2, 2025

NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks.
Via Chartmill · May 31, 2025

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Via Investor's Business Daily · May 29, 2025

NOVO-NORDISK (NYSE:NVO) offers strong profitability, solid growth, and reasonable valuation, making it a compelling choice for value investors. Its financial health and industry-leading margins add further appeal.
Via Chartmill · May 28, 2025

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.
Via The Motley Fool · May 28, 2025
Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted.
Via The Motley Fool · May 27, 2025
President Trump has good news for Novo Nordisk investors, and more may be on the way.
Via The Motley Fool · May 27, 2025